Unwanted advice? Frequency, characteristics and outcomes of negative advisory committee votes for FDA approved drugs

2 May 2022 - Substantial controversy arose in 2021 when the FDA approved the Alzheimer’s disease drug aducanumab (Aduhelm) under its ...

Read more →